OXT and major depressive disorder: Indeed, higher oxytocin reactivity has recently been related to greater treatment response and symptom reduction in adults with MDD, supporting the oxytocin system as an important biomarker and moderator of treatment success (Atzil‐Slonim et al., 2022).